11β-hydroxysteroid dehydrogenase-1 as a therapeutic target for metabolic diseases

被引：43

作者：

Fotsch, C ^{[1
]}

Askew, BC ^{[1
]}

Chen, JJ ^{[1
]}

机构：

[1] Amgen Inc, Chem Res & Discovery, Thousand Oaks, CA 91320 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2005年 / 15卷 / 03期

关键词：

11 beta-hydroxysteroid dehydrogenase (11 beta HSD1); diabetes; gluconeogenesis; hydroxysteroid dehydrogenase; inhibitor;

D O I：

10.1517/13543776.15.3.289

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

11 beta-Hydroxysteroid dehydrogenase-1 (11 beta HSD1) is a therapeutic target for Type 2 diabetes that has stimulated the interest of many pharmaceutical companies. Mounting evidence obtained from both preclinical and clinical studies support the contention that inhibiting 11 beta HSD1 will have a therapeutic benefit by lowering glucose output and increasing insulin sensitivity. In just over two years, 21 applications containing 11 beta HSD1 inhibitors have been published. In this review, the target rationale and patent applications from Merck, Novo Nordisk, AstraZeneca, Sterix, Biovitrum, Janssen and Novartis will be discussed.

引用

页码：289 / 303

页数：15

共 31 条

[21]

Pavlova S.I., 2003, PHARM CHEM J, V37, P314, DOI DOI 10.1023/A:1026005931751

[22] Tissue-specific dysregulation of cortisol metabolism in human obesity [J].

Rask, E ;

Olsson, T ;

Söderberg, S ;

Andrew, R ;

Livingstone, DE ;

Johnson, O ;

Walker, BR .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1418-1421

[23] Inhibition of 11β-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension [J].

Rauz, S ;

Cheung, CMG ;

Wood, PJ ;

Coca-Prados, M ;

Walker, EA ;

Murray, PI ;

Stewart, PM .

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2003, 96 (07) :481-490

[24] Chemistry and biochemistry of type 2 diabetes [J].

Ross, SA ;

Gulve, EA ;

Wang, MH .

CHEMICAL REVIEWS, 2004, 104 (03) :1255-1282

[25] Minireview:: 11β-hydroxysteroid dehydrogenase type 1 -: A tissue-specific amplifier of glucocorticoid action [J].

Seckl, JR ;

Walker, BR .

ENDOCRINOLOGY, 2001, 142 (04) :1371-1376

[26] Diabetes mellitus: Pathogenesis and treatment strategies [J].

Skyler, JS .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (17) :4113-4117

[27] 11β-hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes [J].

Stulnig, TM ;

Waldhäusl, W .

DIABETOLOGIA, 2004, 47 (01) :1-11

[28] Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome [J].

Wajchenberg, BL .

ENDOCRINE REVIEWS, 2000, 21 (06) :697-738

[29] CARBENOXOLONE INCREASES HEPATIC INSULIN SENSITIVITY IN MAN - A NOVEL ROLE FOR 11-OXOSTEROID REDUCTASE IN ENHANCING GLUCOCORTICOID RECEPTOR ACTIVATION [J].

WALKER, BR ;

CONNACHER, AA ;

LINDSAY, RM ;

WEBB, DJ ;

EDWARDS, CRW .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (11) :3155-3159

[30] 11β-hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease [J].

Walker, BR ;

Seckl, JR .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (06) :771-783

← 1 2 3 4 →